P53 orchestrates between normal differentiation and cancer

Seminars in Cancer Biology

Volumn 32, Issue , 2015, Pages 10-17

  Rivlin, Noa ^a   Koifman, Gabriela ^a   Rotter, Varda ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Cancer stem cells; Differentiation; P53; Stem cells

Indexed keywords

PROTEIN P53;

ADULT STEM CELL; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL METABOLISM; CELL TRANSFORMATION; EMBRYONIC STEM CELL; HUMAN; MALIGNANT TRANSFORMATION; METABOLIC REGULATION; NEOPLASM; NONHUMAN; NUCLEAR REPROGRAMMING; PROTEIN FUNCTION; REVIEW; TUMOR ESCAPE; TUMOR PROMOTION; ANIMAL; GENETICS; MOUSE; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; HUMANS; MICE; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84929951550     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.12.006     Document Type: Review

References (158)

1. Ben-David U., Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer 2011, 11:268-277.
2. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507.
3. Dreesen O., Brivanlou A.H. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007, 3:7-17.
4. Blum B., Benvenisty N. The tumorigenicity of human embryonic stem cells. Adv Cancer Res 2008, 100:133-158.
5. Knoepfler P.S. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009, 27:1050-1056.
6. Martin G.R. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. PNAS 1981, 78:7634-7638.
7. Herszfeld D., Wolvetang E., Langton-Bunker E., Chung T.L., Filipczyk A.A., Houssami S., et al. CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells. Nat Biotechnol 2006, 24:351-357.
8. Werbowetski-Ogilvie T.E., Bosse M., Stewart M., Schnerch A., Ramos-Mejia V., Rouleau A., et al. Characterization of human embryonic stem cells with features of neoplastic progression. Nat Biotechnol 2009, 27:91-97.
9. Lane D.P. Cancer. p53, guardian of the genome. Nature 1992, 358:15-16.
10. Levine A.J., Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9:749-758.
11. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009, 9:701-713.
12. Rivlin N., Brosh R., Oren M., Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer 2011, 2:466-474.
13. Molchadsky A., Rivlin N., Brosh R., Rotter V., Sarig R. p53 is balancing development, differentiation and de-differentiation to assure cancer prevention. Carcinogenesis 2010.
14. Molchadsky A., Shats I., Goldfinger N., Pevsner-Fischer M., Olson M., Rinon A., et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PloS One 2008, 3:e3707.
15. Shaulsky G., Goldfinger N., Rotter V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res 1991, 51:5232-5237.
16. Matas D., Milyavsky M., Shats I., Nissim L., Goldfinger N. Rotter V. p53 is a regulator of macrophage differentiation. Cell Death Differ 2004, 11:458-467.
17. Aloni-Grinstein R., Zan-Bar I., Alboum I., Goldfinger N., Rotter V. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage. Oncogene 1993, 8:3297-3305.
18. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
19. Barak Y., Juven T., Haffner R. Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993, 12:461-468.
20. Montes de Oca Luna R., Wagner D.S., Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995, 378:203-206.
21. Jones S.N., Roe A.E., Donehower L.A., Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995, 378:206-208.
22. Sah V.P., Attardi L.D., Mulligan G.J., Williams B.O., Bronson R.T., Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995, 10:175-180.
23. Armstrong J.F., Kaufman M.H., Harrison D.J., Clarke A.R. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 1995, 5:931-936.
24. Danilova N., Sakamoto K.M. Lin S. p53 family in development. Mech Dev 2008, 125:919-931.
25. Hu W., Feng Z., Teresky A.K., Levine A.J. p53 regulates maternal reproduction through LIF. Nature 2007, 450:721-724.
26. Rotter V., Schwartz D., Almon E., Goldfinger N., Kapon A., Meshorer A., et al. Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome. PNAS 1993, 90:9075-9079.
27. Beumer T.L., Roepers-Gajadien H.L., Gademan I.S., van Buul P.P., Gil-Gomez G., Rutgers D.H., et al. The role of the tumor suppressor p53 in spermatogenesis. Cell Death Differ 1998, 5:669-677.
28. Tomasini R., Tsuchihara K., Wilhelm M., Fujitani M., Rufini A., Cheung C.C., et al. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 2008, 22:2677-2691.
29. Suh E.K., Yang A., Kettenbach A., Bamberger C., Michaelis A.H., Zhu Z., et al. p63 protects the female germ line during meiotic arrest. Nature 2006, 444:624-628.
30. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 2007, 7:165-168.
31. Evans M.J., Kaufman M.H. Establishment in culture of pluripotential cells from mouse embryos. Nature 1981, 292:154-156.
32. Cervantes R.B., Stringer J.R., Shao C., Tischfield J.A., Stambrook P.J. Embryonic stem cells and somatic cells differ in mutation frequency and type. PNAS 2002, 99:3586-3590.
33. Tichy E.D. Mechanisms maintaining genomic integrity in embryonic stem cells and induced pluripotent stem cells. Exp Biol Med (Maywood) 2011, 236:987-996.
34. Zhao T., Xu Y. p53 and stem cells: new developments and new concerns. Trends Cell Biol 2010, 20:170-175.
35. Fujimori H., Shikanai M., Teraoka H., Masutani M., Yoshioka K. Induction of cancerous stem cells during embryonic stem cell differentiation. J Biol Chem 2012, 287:36777-36791.
36. Lin T., Chao C., Saito S., Mazur S.J., Murphy M.E., Appella E., et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005, 7:165-171.
37. Schmid P., Lorenz A., Hameister H., Montenarh M. Expression of p53 during mouse embryogenesis. Development (Cambridge, England) 1991, 113:857-865.
38. Sabapathy K., Klemm M., Jaenisch R., Wagner E.F. Regulation of ES cell differentiation by functional and conformational modulation of p53. EMBO J 1997, 16:6217-6229.
39. Solozobova V., Blattner C. Regulation of p53 in embryonic stem cells. Exp Cell Res 2010, 316:2434-2446.
40. Menendez S., Goh A.M., Camus S., Ng K.W., Kua N., Badal V., et al. MDM4 downregulates p53 transcriptional activity and response to stress during differentiation. Cell Cycle 2011, 10:1100-1108.
41. Zhang Y., Gao J.S., Tang X., Tucker L.D., Quesenberry P., Rigoutsos I., et al. MicroRNA 125a and its regulation of the p53 tumor suppressor gene. FEBS Lett 2009, 583:3725-3730.
42. Le M.T., Teh C., Shyh-Chang N., Xie H., Zhou B., Korzh V., et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev 2009, 23:862-876.
43. Solozobova V., Rolletschek A., Blattner C. Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage. BMC Cell Biol 2009, 10:46.
44. Han M.K., Song E.K., Guo Y., Ou X., Mantel C., Broxmeyer H.E. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell 2008, 2:241-251.
45. Grandela C., Pera M.F., Grimmond S.M., Kolle G. Wolvetang EJ. p53 is required for etoposide-induced apoptosis of human embryonic stem cells. Stem Cell Res 2007, 1:116-128.
46. Shigeta M., Ohtsuka S., Nishikawa-Torikai S., Yamane M., Fujii S., Murakami K., et al. Maintenance of pluripotency in mouse ES cells without Trp53. Sci Rep 2013, 3:2944.
47. Lee D.F., Su J., Ang Y.S., Carvajal-Vergara X., Mulero-Navarro S., Pereira C.F., et al. Regulation of embryonic and induced pluripotency by aurora kinase-p53 signaling. Cell Stem Cell 2012, 11:179-194.
48. Ungewitter E., Scrable H. Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev 2010, 24:2408-2419.
49. Aladjem M.I., Spike B.T., Rodewald L.W., Hope T.J., Klemm M., Jaenisch R., et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 1998, 8:145-155.
50. Chao C., Saito S., Anderson C.W., Appella E., Xu Y. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. PNAS 2000, 97:11936-11941.
51. Schmidt-Kastner P.K., Jardine K., Cormier M., McBurney M.W. Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines. Oncogene 1998, 16:3003-3011.
52. Chuykin I.A., Lianguzova M.S., Pospelova T.V., Pospelov V.A. Activation of DNA damage response signaling in mouse embryonic stem cells. Cell Cycle 2008, 7:2922-2928.
53. Li M., He Y., Dubois W., Wu X., Shi J., Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol Cell 2012, 46:30-42.
54. Hishida T., Nozaki Y., Nakachi Y., Mizuno Y., Iseki H., Katano M., et al. Sirt1, p53, and p38(MAPK) are crucial regulators of detrimental phenotypes of embryonic stem cells with Max expression ablation. Stem Cells 2012, 30:1634-1644.
55. Qin H., Yu T., Qing T., Liu Y., Zhao Y., Cai J., et al. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. J Biol Chem 2007, 282:5842-5852.
56. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
57. Maimets T., Neganova I., Armstrong L., Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene 2008, 27:5277-5287.
58. Lee K.H., Li M., Michalowski A.M., Zhang X., Liao H., Chen L., et al. A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells. PNAS 2010, 107:69-74.
59. Kanatsu-Shinohara M., Inoue K., Lee J., Yoshimoto M., Ogonuki N., Miki H., et al. Generation of pluripotent stem cells from neonatal mouse testis. Cell 2004, 119:1001-1012.
60. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
61. Mali P., Ye Z., Hommond H.H., Yu X., Lin J., Chen G., et al. Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. Stem Cells 2008, 26:1998-2005.
62. Hong H., Takahashi K., Ichisaka T., Aoi T., Kanagawa O., Nakagawa M., et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 2009, 460:1132-1135.
63. Kawamura T., Suzuki J., Wang Y.V., Menendez S., Morera L.B., Raya A., et al. Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 2009, 460:1140-1144.
64. Li H., Collado M., Villasante A., Strati K., Ortega S., Canamero M., et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 2009, 460:1136-1139.
65. Marion R.M., Strati K., Li H., Murga M., Blanco R., Ortega S., et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 2009, 460:1149-1153.
66. Sarig R., Rivlin N., Brosh R., Bornstein C., Kamer I., Ezra O., et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells. J Exp Med 2010.
67. Takenaka C., Nishishita N., Takada N., Jakt L.M., Kawamata S. Effective generation of iPS cells from CD34(+) cord blood cells by inhibition of p53. Exp Hematol 2009.
68. Zhao Y., Yin X., Qin H., Zhu F., Liu H., Yang W., et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 2008, 3:475-479.
69. Tapia N., Scholer H.R. p53 connects tumorigenesis and reprogramming to pluripotency. J Exp Med 2010, 207:2045-2048.
70. Samavarchi-Tehrani P., Golipour A., David L., Sung H.K., Beyer T.A., Datti A., et al. Functional genomics reveals a BMP-driven mesenchymal-to-epithelial transition in the initiation of somatic cell reprogramming. Cell Stem Cell 2010, 7:64-77.
71. Brosh R., Assia-Alroy Y., Molchadsky A., Bornstein C., Dekel E., Madar S., et al. p53 counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition. Cell Death Differ 2013, 20:312-320.
72. Yi L., Lu C., Hu W., Sun Y., Levine A.J. Multiple roles of p53 related pathways in somatic cell reprogramming and stem cell differentiation. Cancer Res 2012.
73. Choi Y.J., Lin C.P., Ho J.J., He X., Okada N., Bu P., et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 2011, 13:1353-1360.
74. Wei J.S., Song Y.K., Durinck S., Chen Q.R., Cheuk A.T., Tsang P., et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008, 27:5204-5213.
75. Lin C.P., Choi Y.J., Hicks G.G., He L. The emerging functions of the p53-miRNA network in stem cell biology. Cell Cycle 2012, 11:2063-2072.
76. Xu N., Papagiannakopoulos T., Pan G., Thomson J.A., Kosik K.S. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 2009, 137:647-658.
77. Wang J., He Q., Han C., Gu H., Jin L., Li Q., et al. p53-facilitated miR-199a-3p regulates somatic cell reprogramming. Stem Cells 2012, 30:1405-1413.
78. Jain A.K., Allton K., Iacovino M., Mahen E., Milczarek R.J., Zwaka T.P., et al. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol 2012, 10:e1001268.
79. Miyoshi N., Ishii H., Nagano H., Haraguchi N., Dewi D.L., Kano Y., et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. Cell Stem Cell 2011, 8:633-638.
80. Neveu P., Kye M.J., Qi S., Buchholz D.E., Clegg D.O., Sahin M., et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell 2010, 7:671-681.
81. Vicente-Duenas C., Romero-Camarero I., Cobaleda C., Sanchez-Garcia I. Function of oncogenes in cancer development: a changing paradigm. Embo J 2013, 32:1502-1513.
82. Velasco-Hernandez T., Vicente-Duenas C., Sanchez-Garcia I. Martin-Zanca D. p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. Cell Cycle 2013, 12:122-132.
83. Gage F.H. Mammalian neural stem cells. Science 2000, 287:1433-1438.
84. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003, 17:1253-1270.
85. Toma J.G., Akhavan M., Fernandes K.J., Barnabe-Heider F., Sadikot A., Kaplan D.R., et al. Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 2001, 3:778-784.
86. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
87. Theise N.D., Saxena R., Portmann B.C., Thung S.N., Yee H., Chiriboga L., et al. The canals of Hering and hepatic stem cells in humans. Hepatology 1999, 30:1425-1433.
88. Liu Y., Elf S.E., Miyata Y., Sashida G., Liu Y., Huang G., et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009, 4:37-48.
89. D'Sa-Eipper C., Leonard J.R., Putcha G., Zheng T.S., Flavell R.A., Rakic P., et al. DNA damage-induced neural precursor cell apoptosis requires p53 and caspase 9 but neither Bax nor caspase 3. Development (Cambridge, England) 2001, 128:137-146.
90. Tedeschi A., Di Giovanni S. The non-apoptotic role of p53 in neuronal biology: enlightening the dark side of the moon. EMBO Rep 2009, 10:576-583.
91. Eizenberg O., Faber-Elman A., Gottlieb E., Oren M., Rotter V., Schwartz M. p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells. Mol Cell Biol 1996, 16:5178-5185.
92. Meletis K., Wirta V., Hede S.M., Nister M., Lundeberg J., Frisen J. p53 suppresses the self-renewal of adult neural stem cells. Development (Cambridge, England) 2006, 133:363-369.
93. Zheng H., Ying H., Yan H., Kimmelman A.C., Hiller D.J., Chen A.J., et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008, 455:1129-1133.
94. Cicalese A., Bonizzi G., Pasi C.E., Faretta M., Ronzoni S., Giulini B., et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.
95. Zhou Z., Flesken-Nikitin A., Nikitin A.Y. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res 2007, 67:5683-5690.
96. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
97. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
98. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
99. Hermann P.C., Bhaskar S., Cioffi M., Heeschen C. Cancer stem cells in solid tumors. Semin Cancer Biol 2010, 20:77-84.
100. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
101. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
102. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
103. Bjerkvig R., Tysnes B.B., Aboody K.S., Najbauer J., Terzis A.J. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005, 5:899-904.
104. Gires O. Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci 2011, 68:4009-4022.
105. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule. Nat Rev Cancer 2011, 11:254-267.
106. Hiraga T., Ito S., Nakamura H. Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res 2013, 73:4112-4122.
107. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
108. Liu C., Kelnar K., Liu B., Chen X., Calhoun-Davis T., Li H., et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 2011, 17:211-215.
109. Godar S., Ince T.A., Bell G.W., Feldser D., Donaher J.L., Bergh J., et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134:62-73.
110. Hermeking H. MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012, 12:613-626.
111. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS One 2009, 4:e6816.
112. Zhang S., Balch C., Chan M.W., Lai H.C., Matei D., Schilder J.M., et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008, 68:4311-4320.
113. Adhikari A.S., Agarwal N., Wood B.M., Porretta C., Ruiz B., Pochampally R.R., et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010, 70:4602-4612.
114. Kang M.K., Hur B.I., Ko M.H., Kim C.H., Cha S.H., Kang S.K. Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma. BMC Neurosci 2008, 9:15.
115. Siemens H., Jackstadt R., Kaller M., Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget 2013, 4:1399-1415.
116. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
117. Siemens H., Jackstadt R., Hunten S., Kaller M., Menssen A., Gotz U., et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10:4256-4271.
118. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
119. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
120. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
121. Schubert J., Brabletz T. p53 Spreads out further: suppression of EMT and stemness by activating miR-200c expression. Cell Res 2011, 21:705-707.
122. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283:14910-14914.
123. Chang C.J., Chao C.H., Xia W., Yang J.Y., Xiong Y., Li C.W., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat Cell Biol 2011, 13:317-323.
124. Kogan-Sakin I., Tabach Y., Buganim Y., Molchadsky A., Solomon H., Madar S., et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 2011, 18:271-281.
125. Dong P., Karaayvaz M., Jia N., Kaneuchi M., Hamada J., Watari H., et al. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene 2013, 32:3286-3295.
126. Jeter C.R., Liu B., Liu X., Chen X., Liu C., Calhoun-Davis T., et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011, 30:3833-3845.
127. Wang M.L., Chiou S.H., Wu C.W. Targeting cancer stem cells: emerging role of Nanog transcription factor. OncoTargets Ther 2013, 6:1207-1220.
128. Zbinden M., Duquet A., Lorente-Trigos A., Ngwabyt S.N., Borges I. Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with GLI1 and p53. EMBO J 2010, 29:2659-2674.
129. Gibbs C.P., Kukekov V.G., Reith J.D., Tchigrinova O., Suslov O.N., Scott E.W., et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005, 7:967-976.
130. Jeter C.R., Badeaux M., Choy G., Chandra D., Patrawala L., Liu C., et al. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 2009, 27:993-1005.
131. Sato A., Okada M., Shibuya K., Watanabe E., Seino S., Suzuki K., et al. Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells. Stem Cell Res 2013, 11:601-610.
132. Shen Y.A., Lin C.H., Chi W.H., Wang C.Y., Hsieh Y.T., Wei Y.H., et al. Resveratrol impedes the stemness, epithelial-mesenchymal transition, and metabolic reprogramming of cancer stem cells in nasopharyngeal carcinoma through p53 activation. Evidence-Based Complementary Altern Med 2013, 2013:590393.
133. Golubovskaya V.M. FAK and Nanog cross talk with p53 in cancer stem cells. Anti-Cancer Agents Med Chem 2013, 13:576-580.
134. Lim S.T., Chen X.L., Lim Y., Hanson D.A., Vo T.T., Howerton K., et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol Cell 2008, 29:9-22.
135. Ho B., Olson G., Figel S., Gelman I., Cance W.G., Golubovskaya V.M. Nanog increases focal adhesion kinase (FAK) promoter activity and expression and directly binds to FAK protein to be phosphorylated. J Biol Chem 2012, 287:18656-18673.
136. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
137. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
138. Chin K.V., Ueda K., Pastan I., Gottesman M.M. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992, 255:459-462.
139. Li L., Wang L., Li L., Wang Z., Ho Y., McDonald T., et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012, 21:266-281.
140. Pang L.Y., Blacking T.M., Else R.W., Sherman A., Sang H.M., Whitelaw B.A., et al. Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway. Vet J (London, England: 1997) 2013, 196:414-423.
141. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
142. Yamakuchi M., Lowenstein C.J. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009, 8:712-715.
143. Kurrey N.K., Jalgaonkar S.P., Joglekar A.V., Ghanate A.D., Chaskar P.D., Doiphode R.Y., et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27:2059-2068.
144. Lessard J., Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
145. Bruggeman S.W., Valk-Lingbeek M.E., van der Stoop P.P., Jacobs J.J., Kieboom K., Tanger E., et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005, 19:1438-1443.
146. Calao M., Sekyere E.O., Cui H.J., Cheung B.B., Thomas W.D., Keating J., et al. Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation. Oncogene 2013, 32:3616-3626.
147. Goldstein I., Ezra O., Rivlin N., Molchadsky A., Madar S., Goldfinger N., et al. p53, a novel regulator of lipid metabolism pathways. J Hepatol 2011.
148. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., et al. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
149. Maddocks O.D., Vousden K.H. Metabolic regulation by p53. J Med Mol (Berlin, Germany) 2011, 89:237-245.
150. Ginestier C., Charafe-Jauffret E. Birnbaum D. p53 and cancer stem cells: the mevalonate connexion. Cell Cycle 2012, 11:2583-2584.
151. Ginestier C., Monville F., Wicinski J., Cabaud O., Cervera N., Josselin E., et al. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 2012, 30:1327-1337.
152. Freed-Pastor W.A., Mizuno H., Zhao X., Langerod A., Moon S.H., Rodriguez-Barrueco R., et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012, 148:244-258.
153. Mao X.G., Song S.J., Xue X.Y., Yan M., Wang L., Lin W., et al. LGR5 is a proneural factor and is regulated by OLIG2 in glioma stem-like cells. Cell Mol Neurobiol 2013, 33:851-865.
154. Ligon K.L., Huillard E., Mehta S., Kesari S., Liu H., Alberta J.A., et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 2007, 53:503-517.
155. Mehta S., Huillard E., Kesari S., Maire C.L., Golebiowski D., Harrington E.P., et al. The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011, 19:359-371.
156. Wang Y., Yang J., Zheng H., Tomasek G.J., Zhang P., McKeever P.E., et al. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 2009, 15:514-526.
157. Flesken-Nikitin A., Hwang C.I., Cheng C.Y., Michurina T.V., Enikolopov G., Nikitin A.Y. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature 2013, 495:241-245.
158. Rodriguez R., Rubio R., Menendez P. Modeling sarcomagenesis using multipotent mesenchymal stem cells. Cell Res 2012, 22:62-77.